The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Culmerciclib (CDK2/4/6 inhibitor) plus fulvestrant in HR+/HER2- advanced breast cancer after progression on CDK4/6i: Preliminary results from a phase II trial.
 
Tao Sun
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Yehui Shi
No Relationships to Disclose
 
Li Cai
No Relationships to Disclose
 
Jin Yang
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Lijia He
No Relationships to Disclose
 
Fan Feng
Employment - Chia Tai Tianqing Pharmaceutical Co., Ltd.
Honoraria - Chia Tai Tianqing Pharmaceutical Co., Ltd.
 
Yang Yu
Employment - Chia Tai Tianqing Pharmaceutical Co., Ltd.
Honoraria - Chia Tai Tianqing Pharmaceutical Co., Ltd.
 
Shaoying Hao
Employment - Chia Tai Tianqing Pharmaceutical Co., Ltd.
Honoraria - Chia Tai Tianqing Pharmaceutical Co., Ltd.
 
Xunqiang Wang
Employment - Chia Tai Tianqing Pharmaceutical Co., Ltd.
Honoraria - Chia Tai Tianqing Pharmaceutical Co., Ltd.